Edwards Lifesciences Corp.’s Sapien 3 platform has been approved for a new indication. The Food and Drug Administration ...

The FDA has approved the SAPIEN 3 platform, a TAVR therapy, for patients with severe aortic stenosis without symptoms.

Darshin Patel discusses the first-of-its-kind Sapien M3 TMVR system's design, development and lessons for other medical ...

The US Food and Drug Administration (FDA) has approved Edwards Lifesciences' SAPIEN 3 transcatheter aortic valve replacement ...

Edwards Lifesciences (NYSE: EW) received FDA approval for its Sapien 3 TAVR for severe aortic stenosis (AS) without symptoms.

The FDA approved Edwards Lifesciences Corp.'s Sapien 3 platform for patients with asymptomatic severe aortic stenosis.

FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR) platform for treatment of severe aortic stenosis ...

The U.S. Food and Drug Administration has approved Edwards Lifesciences' SAPIEN 3 platform, a transcatheter aortic valve replacement (TAVR) therapy, for patients with severe aortic stenosis ...

The US Food and Drugs Administration ( FDA) has approved the Sapien 3 transcatheter aortic valve replacement (TAVR) system ...

Approval of the SAPIEN 3 platform was granted to Edwards Lifesciences. More Information ...